¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×Ü°æÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ g4 _DEBh  
oqHI `Tu  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© Mh>H 5l.1i  
7. 9n  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© (Y\aV+9[  
~aa`Y0Ws],  
1.Co-stimulators (or co-stimulating molecules) LF?83P,UJ#  
>up'`K,  
2.NK-kB C"_f3[Z  
X64OX9:YF  
3.Immunoglobulin superfamily W+V#z8K  
/~V .qisZ  
4.antigen-presenting cell (APC) B5 pM cw  
ww82)m8  
5.death domain ivsp):W  
#z 3tSnmp  
6.CCR and CXCR dHc38zp  
,A9pj k'  
7.Lectin (or mitogen) 5*~Mv<#  
+,<\LIP  
8.Clusters of differentiation, CD) 2j8^Z  
?#idmb}(  
9.B7 family SHS:>V  
[,)yc/{*  
10.Cytotoxic T lymphocyte, CTL) YP{)jAK  
qW[p .jN  
11.IL-15 and IL-15 receptor (IL-15R) 1xg^;3m2  
FLdO  
12.MHC restriction p% ESp&  
Bi2be$nV  
13.Affinity-chromatography N8|=K_;&  
=\.Oc+p4  
14.Cyctosprin A, CsA itb0dF1G  
2MwR jh_  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) ]bCeJE.+)  
Z#YkAQHv5  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© O~F/{: U  
<r]7xsr  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 %\#s@8=2u  
-G&>b D  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ ^p(t*%LM  
?P4@U9i  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 -C.x;@!k  
(UmoG  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© _Ki aeVE  
v<iMlOEt  
ÃâÒßѧרҵ£º V3baEy>=z  
2zR*`9$  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 1L1_x'tT%  
f 'aQ T  
Ïû»¯ÄÚ¿Æ£º (;YO]U4  
|qbCmsY5/  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ /9dV!u!;  
'8>h4s4  
ѪҺ²¡Ñ§×¨Òµ£º c 2j?<F1  
BX$t |t;!m  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»